List of patient-reported quality of life surveys: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
No edit summary
No edit summary
Line 3: Line 3:
==List==
==List==


* '''[[Alzheimer's Disease]].''' The Quality of Life of Carers of Alzheimer’s Disease Patients (ACQLI) is a measure which assesses the quality of life of people who care for Alzheimer's Disease patients. It was developed in 1997 by Galen Research<ref>{{cite web|title=ACQLI|url=http://www.galen-research.com/content/measures/ACQLI%20UK%2030%20Male%20Patient%20-%20First%20page%20sample.pdf|work=Galen-Research.com|publisher=Galen Research|accessdate=11 November 2013}}</ref> and has been used in studies investigating [[rosiglitazone]]<ref>{{cite web|title=Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease|url=http://clinicaltrials.gov/ct2/show/NCT00428090?term=ACQLI&rank=1|work=ClinicalTrials.gov|publisher=U.S. National Institutes of Health|accessdate=11 November 2013}}</ref><ref>{{cite web|title=Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-2)|url=http://clinicaltrials.gov/ct2/show/NCT00348309?term=ACQLI&rank=2|work=ClinicalTrials.gov|publisher=U.S. National Institutes of Health|accessdate=11 November 2013}}</ref><ref>{{cite web|title=Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-3)|url=http://clinicaltrials.gov/ct2/show/NCT00348140?term=ACQLI&rank=3|work=ClinicalTrials.gov|publisher=U.S. National Institutes of Health|accessdate=11 November 2013}}</ref> and the effects of pharmacological treatment<ref>{{cite journal|last=Levy|first=Karen|coauthors=Lanctot, Krista L.; Farber, Shale B.; Li, Abby; Herrmann, Nathan|title=Does Pharmacological Treatment of Neuropsychiatric Symptoms in Alzheimer’s Disease Relieve Caregiver Burden?|journal=Drugs and Aging|year=2012|month=March|volume=29|issue=3|pages=167-179|doi=10.2165/11599140-000000000-00000|url=http://link.springer.com/article/10.2165/11599140-000000000-00000|accessdate=11 November 2013}}</ref>.
* '''[[Ankylosing Spondylitis]].''' The [[Ankylosing Spondylitis Quality of Life (ASQoL) Questionnaire]] was developed Galen Research and published in 2003.<ref name="DowardSp">{{cite journal | last = Doward | first = L.C. | coauthors = Spoorenberg, A., Cook, S.A., Whalley, D., Helliwell, P.S., Kay, L.J., McKenna, S.P., Tennant, A., van der Heijde, D., Chamberlain, M.A. | title = Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis | journal = Annals of the Rheumatic Diseases | volume = 62 | issue = 1 | pages = 20–26 | year = 2003 | doi = 10.1136/ard.62.1.20 | pmid = 12480664 | pmc = 1754293 }}</ref> It has been used in the evaluation of [[adalimumab]]<ref>{{cite journal|last=van der Heijde|first=Desiree M.|coauthors=Revicki, Dennis A.; Gooch, Katherine L.; Wong, Robert L.; Kupper, Hartmut; Harnam, Neesha; Thompson, Chris; Sieper, Joachim; the ATLAS Study Group|title=Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis|journal=Arthritis Research & Therapy|date=17/08/2009|volume=11|issue=4|pages=1–12|doi=10.1186/ar2790}}</ref><ref>{{cite journal|last=Davis Jr.|first=John C.|coauthors=Revicki, Dennis; van der Heijde, Desiree M.F.; Rentz, Anne M.; Wong, Robert L.; Kupper, Hartmut; Luo, Michelle P.|title=Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study.|journal=Arthritis Care & Research|date=15/08/2007|volume=57|issue=6|pages=1050–1057|doi=10.1002/art.22887}}</ref> and [[etanercept]].<ref>{{cite journal|last=Marzo-Ortega|first=Helena|coauthors=McGonagle, Dennis; O'Connor, Philip; Emery, Paul|title=Efficacy of Etanercept in the Treatment of the Entheseal Pathology in Resistant Spondylarthropathy|journal=Arthritis & Rheumatism|date=2001-09-26|volume=44|issue=9|pages=2112–2117|doi=10.1002/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H}}</ref><ref>{{cite journal|last=Marzo-Ortega|first=H|coauthors=McGonagle, D.; Haugeberg, G.; Green, M.J.; Stewart, S.P.; Emery, P.|title=Bone mineral density improvement in spondyloarthropathy after treatment with etanercept.|journal=Annals of Rheumatic Diseases|year=2003|volume=62|pages=1020–1021|doi=10.1136/ard.62.10.1020}}</ref>
* '''[[Ankylosing Spondylitis]].''' The [[Ankylosing Spondylitis Quality of Life (ASQoL) Questionnaire]] was developed Galen Research and published in 2003.<ref name="DowardSp">{{cite journal | last = Doward | first = L.C. | coauthors = Spoorenberg, A., Cook, S.A., Whalley, D., Helliwell, P.S., Kay, L.J., McKenna, S.P., Tennant, A., van der Heijde, D., Chamberlain, M.A. | title = Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis | journal = Annals of the Rheumatic Diseases | volume = 62 | issue = 1 | pages = 20–26 | year = 2003 | doi = 10.1136/ard.62.1.20 | pmid = 12480664 | pmc = 1754293 }}</ref> It has been used in the evaluation of [[adalimumab]]<ref>{{cite journal|last=van der Heijde|first=Desiree M.|coauthors=Revicki, Dennis A.; Gooch, Katherine L.; Wong, Robert L.; Kupper, Hartmut; Harnam, Neesha; Thompson, Chris; Sieper, Joachim; the ATLAS Study Group|title=Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis|journal=Arthritis Research & Therapy|date=17/08/2009|volume=11|issue=4|pages=1–12|doi=10.1186/ar2790}}</ref><ref>{{cite journal|last=Davis Jr.|first=John C.|coauthors=Revicki, Dennis; van der Heijde, Desiree M.F.; Rentz, Anne M.; Wong, Robert L.; Kupper, Hartmut; Luo, Michelle P.|title=Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study.|journal=Arthritis Care & Research|date=15/08/2007|volume=57|issue=6|pages=1050–1057|doi=10.1002/art.22887}}</ref> and [[etanercept]].<ref>{{cite journal|last=Marzo-Ortega|first=Helena|coauthors=McGonagle, Dennis; O'Connor, Philip; Emery, Paul|title=Efficacy of Etanercept in the Treatment of the Entheseal Pathology in Resistant Spondylarthropathy|journal=Arthritis & Rheumatism|date=2001-09-26|volume=44|issue=9|pages=2112–2117|doi=10.1002/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H}}</ref><ref>{{cite journal|last=Marzo-Ortega|first=H|coauthors=McGonagle, D.; Haugeberg, G.; Green, M.J.; Stewart, S.P.; Emery, P.|title=Bone mineral density improvement in spondyloarthropathy after treatment with etanercept.|journal=Annals of Rheumatic Diseases|year=2003|volume=62|pages=1020–1021|doi=10.1136/ard.62.10.1020}}</ref>
* '''[[Asthma]].'''The [[Asthma Life Impact Scale|Asthma Life Impact Scale (ALIS)]] measure was developed in 2010 by Galen Research.<ref name="meads mckenna">{{cite journal|last=Meads|first=David M.|coauthors=McKenna, Stephen P.; Doward, Lynda C.; Pokrzywinski, Robin; Revicki, Dennis; Hunter, Cameron; Glendenning, G. Alastair|title=Development and validation of the Asthma Life Impact Scale (ALIS)|journal=Respiratory Medicine|date=05/2010|volume=104|issue=5|pages=633–643|doi=10.1016/j.rmed.2009.11.023|url=http://www.sciencedirect.com/science/article/pii/S0954611109003874|accessdate=14 October 2013|pmid=20053543}}</ref> It has been translated into 16 languages.<ref>{{cite web|last=Crawford|first=SR|title=Further Developments of the Asthma Life Impact Scale (ALIS)|url=http://www.galen-research.com/content/publications/Galen-ALIS-poster.pdf|work=Galen-Research.com|publisher=Galen Research|accessdate=14 October 2013}}</ref>
* '''[[Asthma]].'''The [[Asthma Life Impact Scale|Asthma Life Impact Scale (ALIS)]] measure was developed in 2010 by Galen Research.<ref name="meads mckenna">{{cite journal|last=Meads|first=David M.|coauthors=McKenna, Stephen P.; Doward, Lynda C.; Pokrzywinski, Robin; Revicki, Dennis; Hunter, Cameron; Glendenning, G. Alastair|title=Development and validation of the Asthma Life Impact Scale (ALIS)|journal=Respiratory Medicine|date=05/2010|volume=104|issue=5|pages=633–643|doi=10.1016/j.rmed.2009.11.023|url=http://www.sciencedirect.com/science/article/pii/S0954611109003874|accessdate=14 October 2013|pmid=20053543}}</ref> It has been translated into 16 languages.<ref>{{cite web|last=Crawford|first=SR|title=Further Developments of the Asthma Life Impact Scale (ALIS)|url=http://www.galen-research.com/content/publications/Galen-ALIS-poster.pdf|work=Galen-Research.com|publisher=Galen Research|accessdate=14 October 2013}}</ref>

Revision as of 10:39, 11 November 2013

This page lists patient-reported quality of life surveys used in the field of medicine, pharmaceuticals, and other scientific trials. These surveys are patient-reported outcome measures, may be questionnaires or surveys, and may be used to evaluate patient satisfaction, symptoms, disease state, or psychological well-being.

List

  1. The Parents’ Index of Quality of Life in Atopic Dermatitis (PiQOL-AD) measures the impact that atopic dermatitis (AD) has on quality of life, from the parents’ perspective.[13] It has 28 items and was developed simultaneously in the United Kingdom, The Netherlands, Germany, Italy, Spain, France and the United States.[14] It has been utilised in several research studies investigating the treatment of paediatric atopic dermatitis with pimecrolimus.[15][16][17] and also in a research study regarding health-related quality of life measurement in children in Ibero-American countries.[18]
  2. The Quality of Life Index for Atopic Dermatitis (QoLIAD) measures the impact that atopic dermatitis (AD) has on a given patient’s quality of life.[19] It is a 25 item questionnaire for patients over the age of 16.[20] The QoLIAD has also been utilized in studies looking into educational intervention,[21][22] topical corticosteroids[23] and pimecrolimus.[24]

References

  1. ^ "ACQLI" (PDF). Galen-Research.com. Galen Research. Retrieved 11 November 2013.
  2. ^ "Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease". ClinicalTrials.gov. U.S. National Institutes of Health. Retrieved 11 November 2013.
  3. ^ "Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-2)". ClinicalTrials.gov. U.S. National Institutes of Health. Retrieved 11 November 2013.
  4. ^ "Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-3)". ClinicalTrials.gov. U.S. National Institutes of Health. Retrieved 11 November 2013.
  5. ^ Levy, Karen (2012). "Does Pharmacological Treatment of Neuropsychiatric Symptoms in Alzheimer's Disease Relieve Caregiver Burden?". Drugs and Aging. 29 (3): 167–179. doi:10.2165/11599140-000000000-00000. Retrieved 11 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  6. ^ Doward, L.C. (2003). "Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis". Annals of the Rheumatic Diseases. 62 (1): 20–26. doi:10.1136/ard.62.1.20. PMC 1754293. PMID 12480664. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  7. ^ van der Heijde, Desiree M. (17/08/2009). "Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis". Arthritis Research & Therapy. 11 (4): 1–12. doi:10.1186/ar2790. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: unflagged free DOI (link)
  8. ^ Davis Jr., John C. (15/08/2007). "Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study". Arthritis Care & Research. 57 (6): 1050–1057. doi:10.1002/art.22887. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  9. ^ Marzo-Ortega, Helena (2001-09-26). "Efficacy of Etanercept in the Treatment of the Entheseal Pathology in Resistant Spondylarthropathy". Arthritis & Rheumatism. 44 (9): 2112–2117. doi:10.1002/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  10. ^ Marzo-Ortega, H (2003). "Bone mineral density improvement in spondyloarthropathy after treatment with etanercept". Annals of Rheumatic Diseases. 62: 1020–1021. doi:10.1136/ard.62.10.1020. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  11. ^ Meads, David M. (05/2010). "Development and validation of the Asthma Life Impact Scale (ALIS)". Respiratory Medicine. 104 (5): 633–643. doi:10.1016/j.rmed.2009.11.023. PMID 20053543. Retrieved 14 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  12. ^ Crawford, SR. "Further Developments of the Asthma Life Impact Scale (ALIS)" (PDF). Galen-Research.com. Galen Research. Retrieved 14 October 2013.
  13. ^ Arnold, RJG (2005). "PSK8 IMPACT OF ATOPIC DERMATITIS ON THE QUALITY-OF-LIFE OF PARENTS OF CHILDREN WITH ATOPIC DERMATITIS". Value in Health. 8 (3): 332. doi:10.1016/S1098-3015(10)62872-0. Retrieved 25 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  14. ^ McKenna, Stephen P. (2005). "International development of the Parents' Index of Quality of Life in Atopic Dermatitis (PIQoL-AD)". Quality of Life Research. 14 (1): 231–241. doi:10.1007/s11136-004-4231-z. PMID 15789957. Retrieved 28 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  15. ^ McKenna, S.P. (2006). "Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel®, SDZ ASM 981): impact on quality of life and health-related quality of life". Journal of the European Academy of Dermatology and Venereology. 20 (3): 248–254. doi:10.1111/j.1468-3083.2006.01383.x. PMID 16503881. Retrieved 28 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  16. ^ Wahn, Ulrich (2002). "Efficacy and Safety of Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Children". Pediatrics. 110 (1): e2. doi:10.1542/peds.110.1.e2. PMID 12093983. Retrieved 28 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  17. ^ Kapp, Alexander (2002). "Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug". Journal of Allergy and Clinical Immunology. 110 (2): 227–284. doi:10.1067/mai.2002.126500. Retrieved 28 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  18. ^ Rajmil, Luis (2012-03-01). "Health-Related Quality of Life Measurement in Children and Adolescents in Ibero-American Countries, 2000 to 2010". Value in Health. 15 (2): 312–322. doi:10.1016/j.jval.2011.11.028. PMID 22433763. Retrieved 25 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  19. ^ Meads, D.M. (2005). "PSK6 INTERPRETING SCORES ON THE QUALITY OF LIFE INDEX FOR ATOPIC DERMATITIS (QOLIAD)". Value in Health. 8 (3): 331–332. doi:10.1016/S1098-3015(10)62870-7. Retrieved 28 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  20. ^ Ehlken, B. (2003). "PSN12 QUALITY-OF-LIFE IN PATIENTS SUFFERING FROM ATOPIC DERMATITIS IN GERMANY". Value in Health. 6 (6): 787–788. doi:10.1016/S1098-3015(10)62005-0. Retrieved 28 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  21. ^ Lambert, J. (2011). "A novel multidisciplinary educational programme for patients with chronic skin diseases: Ghent pilot project and first results". Archives of Dermatological Research. 303 (1): 57–63. doi:10.1007/s00403-010-1082-z. PMID 20842368. Retrieved 28 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  22. ^ Bostoen, J. (2012). "An educational programme for patients with psoriasis and atopic dermatitis: a prospective randomized controlled trial". The British Journal of Dermatology. 167 (5): 1025–1031. doi:10.1111/j.1365-2133.2012.11113.x. PMID 22709422. Retrieved 28 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  23. ^ Moed, Heleen (2012). Moed, Heleen (ed.). "Different strategies for using topical corticosteroids for established eczema". Cochrane Database of Systematic Reviews (10). doi:10.1002/14651858.CD010080. Retrieved 28 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  24. ^ Lecomte, P. (2006). "PSK6 BELGIAN DRUG UTILISATION STUDY OF ELIDEL® IN ROUTINE PRACTICE IN ATOPIC DERMATITIS". Value in Health. 9 (6): A268. doi:10.1016/S1098-3015(10)63408-0. Retrieved 28 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  25. ^ Dawson, J (1998). "Questionnaire on the perceptions of patients about total knee replacement". Journal of Bone and Joint Surgery. 80: 63–69. PMID 9460955. {{cite journal}}: |access-date= requires |url= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  26. ^ Xie F, Ye H, Zhang Y, Liu X, Lei T, Li S (November 2010). "Extension from inpatients to outpatients: validity and reliability of the Oxford Knee Score in measuring health outcomes in patients with knee osteoarthritis." International Journal of Rheumatic Diseases. doi:10.1111/j.1756-185X.2010.01580.x [1]
  27. ^ Weldam, Saskia W.M. (05/2013). "Evaluation of Quality of Life instruments for use in COPD care and research: A systematic review". International Journal of Nursing Studies. 50 (5): 688–707. doi:10.1016/j.ijnurstu.2012.07.017. PMID 22921317. Retrieved 11 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  28. ^ "Measures Database". Galen-Research.com. Galen Research. Retrieved 11 October 2013.
  29. ^ Lopez-Campos, Jose Luis (2009). "Importance of fatigue, sleep quality and mood in patients with chronic obstructive pulmonary disease and the need for measurement instruments". Archivos de Bronconeumologia. 45 (5): 2–6. doi:10.1016/S0300-2896(09)72948-5. Retrieved 14 October 2013.
  30. ^ Amir, Marianne (2002). "Psychometric Properties of the SF-12 (Hebrew Version) in a Primary Care Population in Israel". Medical Care. 40 (10): 918–928. doi:10.1097/00005650-200210000-00009. PMID 12395025. Retrieved 21 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  31. ^ McKenna, Stephen P. (1992). "A new measure of quality of life in depression: Testing the reliability and construct validity of the QLDS". Health Policy. 22 (3): 321–330. Retrieved 22 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  32. ^ Baca Baldomero, E (2003). "Quality of life, in depressed patients in Primary Health Care setting. Effectiveness and safety of venlafaxine extended release". Actas españolas de psiquiatría. 31 (6): 331–338. Retrieved 22 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  33. ^ Detke, Michael J. (2002). "Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression". Journal of Psychiatric Research. 36 (6): 383–390. Retrieved 22 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  34. ^ Hudson, James I. (2007). "Duloxetine in the treatment of major depressive disorder: an open-label study". BMC Psychiatry. 7 (43). doi:10.1186/1471-244X-7-43. Retrieved 22 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: unflagged free DOI (link)
  35. ^ Kornstein, Susan G. (2006). "Duloxetine Efficacy for Major Depressive Disorder in Male vs. Female Patients: Data From 7 Randomized, Double-Blind, Placebo-Controlled Trials". Journal of Clinical Psychiatry. 67: 761–770. Retrieved 22 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  36. ^ Dunner, David L. (2001). "Improved Health-Related Quality of Life and Reduced Productivity Loss After Treatment With Bupropion Sustained Release: A Study in Patients With Major Depression". Primary Care Companion to The Journal of Clinical Psychiatry. 3 (1): 10–16. Retrieved 22 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  37. ^ Hunt, Sonja M.; McKenna, S.P.; McEwen, J.; Williams, Jan; Papp, Evelyn (1981). "The Nottingham health profile: Subjective health status and medical consultations". Social Science & Medicine. Part A: Medical Psychology & Medical Sociology. 15 (3): 221–9. doi:10.1016/0271-7123(81)90005-5. PMID 6973203.
  38. ^ Ebrahim, Shah; Barer, David; Nouri, Fiona (1986). "Use of the Nottingham Health Profile with patients after a stroke". Journal of Epidemiology & Community Health. 40 (2): 166–9. doi:10.1136/jech.40.2.166. JSTOR 25566637. PMC 1052513. PMID 3746178.
  39. ^ Hunt, SM; McEwen, J; McKenna, SP (1985). "Measuring health status: A new tool for clinicians and epidemiologists". The Journal of the Royal College of General Practitioners. 35 (273): 185–8. PMC 1960139. PMID 3989783.
  40. ^ Johansen, K. L.; Finkelstein, F. O.; Revicki, D. A.; Evans, C.; Wan, S.; Gitlin, M.; Agodoa, I. L. (2011). "Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients". Nephrology Dialysis Transplantation. 27 (6): 2418–25. doi:10.1093/ndt/gfr697. PMID 22187314.
  41. ^ Behan, Lucy-Ann; Rogers, Bairbre; Hannon, Mark J.; O'Kelly, Patrick; Tormey, William; Smith, Diarmuid; Thompson, Christopher J.; Agha, Amar (2011). "Optimizing glucocorticoid replacement therapy in severely adrenocorticotropin-deficient hypopituitary male patients". Clinical Endocrinology. 75 (4): 505–13. doi:10.1111/j.1365-2265.2011.04074.x. PMID 21521342.
  42. ^ Aydemir, G; Tezer, M S; Borman, P; Bodur, H; Unal, A (2006). "Treatment of tinnitus with transcutaneous electrical nerve stimulation improves patients' quality of life". The Journal of Laryngology & Otology. 120 (6): 442–5. doi:10.1017/S0022215106000910. PMID 16556347.
  43. ^ a b Wirén, L.; Whalley, D; McKenna, S; Wilhelmsen, L (2000). "Application of a disease-specific, quality-of-life measure (QoL-AGHDA) in growth hormone-deficient adults and a random population sample in Sweden: Validation of the measure by Rasch analysis". Clinical Endocrinology. 52 (2): 143–52. doi:10.1046/j.1365-2265.2000.00899.x. PMID 10671940.
  44. ^ Moock, Joern; Friedrich, Nele; Völzke, Henry; Spielhagen, Christin; Nauck, Matthias; Koltowska-Häggström, Maria; Buchfelder, Michael; Wallaschofski, Henri; Kohlmann, Thomas (2011). "Prediction of improvement in quality of life (QoL-AGHDA) in adults with growth hormone deficiency by normative reference limits: Data of the German KIMS cohort". Growth Hormone & IGF Research. 21 (5): 272–8. doi:10.1016/j.ghir.2011.07.005. PMID 21865066.
  45. ^ Gilet, Hélène; Chachuat, Anne; Viala-Danten, Muriel; Auzière, Sébastien; Koltowska-Häggström, Maria (2010). "Application of the Disease-Specific Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) Questionnaire in a General Population: Results from a French Panel Study". Value in Health. 13 (4): 495–500. doi:10.1111/j.1524-4733.2009.00689.x. PMID 20102556.
  46. ^ Badia, X.; Lucas, A.; Sanmartí, A.; Roset, M.; Ulied, A. (1998). "One-year follow-up of quality of life in adults with untreated growth hormone deficiency". Clinical Endocrinology. 49 (6): 765–71. doi:10.1046/j.1365-2265.1998.00634.x. PMID 10209564.
  47. ^ Mukherjee, A.; Tolhurst-Cleaver, S; Ryder, WD; Smethurst, L; Shalet, SM (2004). "The Characteristics of Quality of Life Impairment in Adult Growth Hormone (GH)-Deficient Survivors of Cancer and Their Response to GH Replacement Therapy". Journal of Clinical Endocrinology & Metabolism. 90 (3): 1542–9. doi:10.1210/jc.2004-0832. PMID 15613427.
  48. ^ Gutiérrez, Lia P.; Kołtowska-Häggström, Maria; Jönsson, Peter J.; Mattsson, Anders F.; Svensson, Dag; Westberg, Björn; Luger, Anton (2008). "Registries as a tool in evidence-based medicine: Example of KIMS (Pfizer International Metabolic Database)". Pharmacoepidemiology and Drug Safety. 17 (1): 90–102. doi:10.1002/pds.1510. PMID 17957812.
  49. ^ Patrick, Donald L. (07/2000). "Further Development and Testing of the Migraine-Specific Quality of Life (MSQOL) Measure". Headache: The Journal of Head and Face Pain. 40 (7): 550–560. doi:10.1046/j.1526-4610.2000.00086.x. Retrieved 8 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  50. ^ Garcia-Monco, JC (08/2007). "Impact of preventive therapy with nadolol and topiramate on the quality of life of migraine patients". Cephalalgia. 27 (8): 920–928. doi:10.1111/j.1468-2982.2007.01367.x. Retrieved 8 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  51. ^ Spigt, Mark (2011). "A randomized trial on the effects of regular water intake in patients with recurrent headaches". Family Practice: 1–6. doi:10.1093/fampra/cmr112. Retrieved 8 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  52. ^ Merelle, SYM (02/2008). "Migraine patients as trainers of their fellow patients in non-pharmacological preventive attack management: short-term effects of a randomized controlled trial". Cephalalgia. 28 (2): 127–138. doi:10.1111/j.1468-2982.2007.01472.x. Retrieved 8 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  53. ^ Doward, L.C. (2009). "The development of patient-reported outcome indices for multiple sclerosis (PRIMUS)". Multiple Sclerosis. 15 (9): 1092–1102. doi:10.1177/1352458509106513. Retrieved 8 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  54. ^ Ziemssen, T. (10/2012). "Study design and first interim results of a registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients in Germany (PANGAEA)". Multiple Sclerosis. 18 (4): 222. doi:10.1177/1352458512459019. Retrieved 9 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  55. ^ T., van Lokven (20/10/2011). "Study design of a non-interventional registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients (PANGAEA)". 5th Joint triennial congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis. Amsterdam, The Netherlands. Retrieved 09/10/2013. {{cite conference}}: Check date values in: |accessdate= and |date= (help); Unknown parameter |booktitle= ignored (|book-title= suggested) (help); Unknown parameter |coauthors= ignored (|author= suggested) (help); line feed character in |booktitle= at position 69 (help)
  56. ^ Cascione, Mark (12/02/2013). "Patient-Reported Treatment Satisfaction, Reasons for Therapy Change, and Health-Related Quality of Life at Baseline from the Trial To Evaluate Patient OutComes, Safety and Tolerability of Fingolimod". Neurology. 80 (1). Retrieved 9 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  57. ^ Maurer, M (15/10/2012). "Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients". Multiple Sclerosis. 19 (5): 631–638. doi:10.1177/1352458512463481. Retrieved 9 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  58. ^ a b de Jong, Z. (1997). "The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument". Rheumatology. 36 (8): 878–883. doi:10.1093/rheumatology/36.8.878. Retrieved 30 September 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  59. ^ Adams, Jo (2013). "Literacy levels required to complete routinely used patient-reported outcome measures in rheumatology". Rheumatology. 52 (3): 460–464. doi:10.1093/rheumatology/kes296. Retrieved 30 September 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  60. ^ Dougados, Maxime (2013). "Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)". Annals of Rheumatic Disease. 72 (1): 43–50. doi:10.1136/annrheumdis-2011-201282. Retrieved 2 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  61. ^ "Efficacy of tocilizumab in patients with rheumatoid arthritis". Current Controlled Trials. Springer Science+Business Media. Retrieved 2 October 2013.
  62. ^ Quinn, Mark A. (07/01/2005). "Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial". Arthritis & Rheumatism. 52 (1): 27–35. doi:10.1002/art.20712. Retrieved 2 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  63. ^ Bejarano, Victoria (2010). "Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis". Rheumatology. 49 (10): 1971–1974. doi:10.1093/rheumatology/keq194. Retrieved 2 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  64. ^ McKenna, Stephen P. (21/08/2008). "Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses" (PDF). Health and Quality of Life Outcomes. 6 (65): 1–8. doi:10.1186/1477-7525-6-65. Retrieved 2 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: unflagged free DOI (link)
  65. ^ McKenna, S.P. (2006). "The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): A measure of health-related quality of life and quality of life for patients with pulmonary hypertension" (PDF). Quality of Life Research. 15: 103–115. doi:10.1007/s11136-005-3513-4. Retrieved 2 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  66. ^ "Measures Database". Galen-Research.com. Galen Research. Retrieved 2 October 2013.
  67. ^ Channick, Richard N. (24/01/2012). "Inhaled treprostinil: a therapeutic review". Drug Design, Development and Therapy. 6: 19–28. doi:10.2147/DDDT.S19281. Retrieved 2 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: unflagged free DOI (link)
  68. ^ Chen, Hubert (2013). "Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension". Health And Quality Of Life Outcomes. 11 (31): 1–8. doi:10.1186/1477-7525-11-31. Retrieved 2 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: unflagged free DOI (link)
  69. ^ Tay, Edgar L.W. (16/06/2011). "Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy". International Journal of Cardiology. 149 (3): 372–376. doi:10.1016/j.ijcard.2010.02.020. Retrieved 2 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  70. ^ Suntharalingam, Jay (2008). "Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary Hypertension". CHEST. 134 (2): 229–236. doi:10.1378/chest.07-2681. Retrieved 2 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  71. ^ Brodszky, V (08/2010). "Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey". Scandinavian Journal of Rheumatology. 39 (4): 303–309. doi:10.3109/03009740903468982. PMID 20166848. Retrieved 9 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  72. ^ McKenna, S (02/2004). "Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis". Annals of Rheumatic Diseases. 63 (2): 162–169. doi:10.1136/ard.2003.006296. PMC 1754880. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  73. ^ Marzo-Ortega, Helena (2007). "Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis". Annals of Rheumatic Diseases. 66 (6): 778–781. doi:10.1136/ard.2006.063818. Retrieved 9 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  74. ^ "A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)". ClinicalTrials.gov. Abbott. Retrieved 9 October 2013.
Retrieved from "https://en.wikipedia.org/w/index.php?title=List_of_patient-reported_quality_of_life_surveys&oldid=581165949"